title: Successful improvement of frequency and symptoms of premature complexes after oral magnesium administration.
abstract: BACKGROUND
  Premature ventricular and supraventricular complexes (PVC and PsVC) are frequent and often symptomatic. The magnesium (Mg) ion plays a role in the physiology of cell membranes and cardiac rhythm.
  
  
  OBJECTIVE
  We evaluated whether the administration of Mg Pidolate (MgP) in patients with PVC and PsVC is superior to placebo (P) in improving symptoms and arrhythmia frequency.
  
  
  METHODS
  Randomized double-blind study with 60 consecutive symptomatic patients with more than 240 PVC or PsVC on 24-hour Holter monitoring who were selected to receive placebo (P) or MgP. To evaluate symptom improvement, a categorical and a specific questionnaire for symptoms related to PVC and PsVC was made. Improvement in premature complex density (PCD) per hour was considered significant if percentage reduction was >70% after treatment. The dose of MgP was 3.0 g/day for 30 days, equivalent to 260 mg of Mg element. Any patient had structural heart disease or renal failure.
  
  
  RESULTS
  Of the 60 patients, 33 were female (55%). Ages ranged from 16 to 70 years old. In the MgP group, 76.6% of patients had a PCD reduction >70%, 10% of them >50% and only 13.4% <50%. In the P group, 40% showed slight improvement, <30%, in the PC frequency (p < 0.001). Symptom improvement was achieved in 93.3% of patients in the MgP group, compared with only 16.7% in the P group (p < 0.001).
  
  
  CONCLUSIONS
  Oral Mg supplementation decreases PCD, resulting in symptom improvement.
authors.affiliation: Instituto do Coração, Universidade de São Paulo. cnmfalco@cardiol.br
authors.forename: Cristina Nadja Muniz Lima De
authors.initials: CN
authors.lastname: Falco
authors.forename: César
authors.initials: C
authors.lastname: Grupi
authors.forename: Eduardo
authors.initials: E
authors.lastname: Sosa
authors.forename: Maurício
authors.initials: M
authors.lastname: Scanavacca
authors.forename: Denise
authors.initials: D
authors.lastname: Hachul
authors.forename: Sissy
authors.initials: S
authors.lastname: Lara
authors.forename: Luciana
authors.initials: L
authors.lastname: Sacilotto
authors.forename: Cristiano F
authors.initials: CF
authors.lastname: Pisani
authors.forename: José A F
authors.initials: JA
authors.lastname: Ramires
authors.forename: Francisco
authors.initials: F
authors.lastname: Darrieux
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018880:Atrial Premature Complexes / Q000188:drug therapy* / Q000517:prevention & control; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015990:Placebo Effect; D011761:Pyrrolidonecarboxylic Acid / Q000008:administration & dosage*; D018709:Statistics, Nonparametric; D013997:Time Factors; D016896:Treatment Outcome; D018879:Ventricular Premature Complexes / Q000188:drug therapy* / Q000517:prevention & control; D055815:Young Adult
chemical_list: D011761:Pyrrolidonecarboxylic Acid